Kwality Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
KPL
Pharmaceuticals
Share Price BSE
₹1499.05
▼
-54.10 (-3.48%)
As of April 13, 2026, the Kwality Pharmaceuticals share price (BSE: KPL) is ₹1,499.05, down 3.48% from the previous close, with shares trading between ₹1,477.00 and ₹1,544.00, and a 52-week range of ₹682.05–₹1,662.90.
Browse Kwality Pharmaceuticals annual reports to support your investment research.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Kwality Pharmaceuticals Market Cap
₹1,611.57 Cr.
KPL P/E Ratio (TTM)
27.55
Kwality Pharmaceuticals P/B Ratio
5.38
EPS (TTM)
₹38.36
Dividend Yield
-
Debt to Equity
0.43
KPL 52 Week High
₹1662.90
Kwality Pharmaceuticals 52 Week Low
₹682.05
Operating Margin
22.00%
Profit Margin
12.82%
KPL Revenue (TTM)
₹117.00
EBITDA
₹27.00
Net Income
₹15.00
Total Assets
₹447.00
Total Equity
₹262.00
Kwality Pharmaceuticals Share Price History - Stock Screener Chart
Screen KPL historical share price movements with interactive charts. Analyze price trends and patterns.
Kwality Pharmaceuticals Company Profile - Fundamental Screener
Screen Kwality Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for KPL shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE552U01010
Kwality Pharmaceuticals Balance Sheet Screener
Screen KPL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 447 | 394 | 354 | 341 | 166 | 133 | 105 | 96 | 71 | 51 |
| Current Assets | 284 | 243 | 207 | 228 | 106 | 89 | 75 | 75 | 53 | 38 |
| Fixed Assets | 146 | 139 | 121 | 92 | 57 | 43 | 29 | 20 | 17 | 13 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 15 | 20 | 29 | 21 | 28 | 20 | 8 | 6 | 4 | 3 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 262 | 223 | 199 | 180 | 60 | 45 | 36 | 29 | 25 | 21 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 5 | 5 |
| Reserves & Surplus | 254 | 214 | 190 | 171 | 51 | 36 | 27 | 19 | 20 | 17 |
Kwality Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Kwality Pharmaceuticals income statement and profit fundamentals.
Analyze KPL quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Kwality Pharmaceuticals share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 117 | 112 | 112 | 124 | 93 | 80 | 90 | 85 | 70 | 68 | 70 | 79 | 66 | 71 | 57 |
| Expenses | 90 | 87 | 86 | 94 | 78 | 63 | 70 | 67 | 74 | 54 | 54 | 61 | 48 | 52 | 40 |
| EBITDA | 27 | 25 | 26 | 30 | 14 | 18 | 20 | 18 | -4 | 14 | 16 | 17 | 18 | 18 | 17 |
| Operating Profit % | 22.00% | 22.00% | 23.00% | 24.00% | 15.00% | 22.00% | 22.00% | 21.00% | -7.00% | 20.00% | 22.00% | 21.00% | 25.00% | 26.00% | 28.00% |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 4 | 5 | 5 | 5 | 3 | 3 | 4 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 1 | 1 | 1 |
| Profit Before Tax | 19 | 17 | 19 | 22 | 6 | 11 | 13 | 11 | -10 | 7 | 8 | 10 | 14 | 14 | 12 |
| Tax | 5 | 5 | 4 | 6 | 2 | 3 | 4 | 3 | -2 | 2 | 2 | 2 | 4 | 4 | 2 |
| Net Profit | 15 | 12 | 14 | 16 | 4 | 8 | 9 | 9 | -7 | 5 | 6 | 8 | 11 | 11 | 9 |
| EPS | 13.95 | 11.49 | 13.60 | 15.42 | 4.08 | 8.04 | 8.15 | 8.21 | -7.23 | 5.10 | 5.99 | 7.39 | 9.97 | 9.99 | 8.82 |
Kwality Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen KPL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 53 | 43 | 41 | 61 | 27 | 6 | 14 | -1 | 4 | -3 |
| Investing Activities | -29 | -26 | -48 | -63 | -23 | -18 | -12 | -6 | -7 | -3 |
| Financing Activities | -14 | -17 | 1 | 6 | 1 | 12 | -2 | 5 | 5 | 6 |
| Net Cash Flow | 10 | -1 | -6 | 3 | 4 | 0 | 0 | -1 | 2 | 0 |
Kwality Pharmaceuticals Shareholding Pattern Screener
See Kwality Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Kwality Pharmaceuticals promoter holding and ownership changes for KPL on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 54.83% | 54.83% | 54.83% | 54.83% | 54.83% | 54.83% | 54.83% | 54.83% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.50% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.32% | 0.33% | 0.33% | 0.33% | 0.00% | 0.00% | 0.02% | 0.03% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 33.39% | 33.32% | 33.68% | 33.02% | 31.70% | 31.78% | 32.78% | 33.25% |
| Other Holding | 11.47% | 11.52% | 11.16% | 11.32% | 13.47% | 13.40% | 12.38% | 11.90% |
| Shareholder Count | 9,420 | 10,115 | 11,595 | 10,709 | 5,695 | 5,273 | 7,487 | 8,947 |
Kwality Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Kwality Pharmaceuticals dividend history with payout and yield data.
View Kwality Pharmaceuticals dividend details including ex-dates and amounts for KPL stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.60 | 1.46% |
Kwality Pharmaceuticals Stock Index Membership
See which indices include Kwality Pharmaceuticals stock.
Check KPL index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Kwality Pharmaceuticals Market Events Screener - Corporate Actions
Get Kwality Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Kwality Pharmaceuticals stock events that may affect KPL share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 3.14% | ||
| Annual General Meeting | NA | -11.48% | ||
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 8.46% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -1.90% |
| 2025-08-11 | 2025-08-11 | Quarterly Result Announcement | NA | 0.73% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 12.45% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -2.47% |
| 2024-10-30 | 2024-10-30 | Quarterly Result Announcement | NA | -0.73% |
| 2017-10-11 | 2017-10-12 | Bonus | 1:1 | - |
Kwality Pharmaceuticals Competitors Screener - Peer Comparison
Screen KPL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 397,066 | 37.62 | 54,729 | 9.71% | 10,980 | 34.03 |
| Divis Laboratories | 162,374 | 63.80 | 9,712 | 18.67% | 2,191 | 53.67 |
| Torrent Pharmaceuticals | 140,631 | 60.97 | 11,539 | 6.99% | 1,911 | 47.83 |
| Lupin | 106,665 | 22.48 | 22,910 | 13.74% | 3,306 | 57.51 |
| Dr Reddys Laboratories | 102,845 | 18.32 | 33,741 | 16.73% | 5,725 | 45.58 |
| Cipla | 99,317 | 21.81 | 28,410 | 7.12% | 5,291 | 40.75 |
| Zydus Life Science | 92,111 | 18.06 | 23,511 | 18.55% | 4,615 | 57.32 |
| Mankind Pharma | 85,822 | 47.03 | 12,744 | 20.90% | 2,007 | 51.63 |
| Aurobindo Pharma | 78,373 | 22.33 | 32,346 | 9.43% | 3,484 | 65.82 |
| Alkem Laboratories | 65,043 | 26.50 | 13,458 | 3.70% | 2,216 | 53.68 |
Kwality Pharmaceuticals Company Announcements - News Screener
Screen KPL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-30 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-03-30 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-03-26 | Closure of Trading Window | - |
| 2026-03-10 | Update On Bioequivalence (BE) Program - Successful Completion Of Phase 1 By Kwality Pharmaceuticals Ltd. | - |
| 2026-03-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-27 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-26 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-02-20 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-12 | Investor Presentation Of Financial Results For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-02-12 | Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025 | - |
| 2026-02-12 | Board Meeting Outcome for Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-02-02 | Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended On 31St December 2025. | - |
| 2026-01-28 | Board Meeting Outcome for Appointment Of Mr. Bhavesh Mahajan (DIN: 09614108) As Additional Independent Director Of The Company | - |